A Phase I Dose Escalation Study Evaluating The Safety And Tolerability Of A Novel Anti-Her2 Antibody-Drug Conjugate (Pf-06804103) In Patients With Her2-Positive Solid Tumors.

Funda Meric-Bernstam,Emiliano Calvo,Victor Moreno,Hyun Cheol Chung,Yeon Hee Park,Yung-Jue Bang,Lee S. Rosen,Monica M. Mita,Ignacio Garrido-Laguna,Abraham C.F. Leung, Harman Dube,Wei Zhong,Xiaoying Chen, Rula Dawaher,Giuseppe Curigliano

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 23|浏览39

暂无评分

摘要

1039Background: PF-06804103 is an anti-HER2 immunoglobulin G1 antibody-drug conjugate (ADC), comprising an anti-HER2 monoclonal antibody conjugated with a cleavable linker to the cytotoxic agent Au...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要